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Summary  Obesity  hypoventilation  syndrome  (OHS)  is  often  associated  with  pulmonary  hyper-
tension (PH),  and  noninvasive  bi-level  positive  airway  pressure  therapy  is  indicated  as  ﬁrst-line
treatment.  However,  its  effect  in  reducing  pulmonary  arterial  pressure  is  insufﬁcient  in  manysyndrome;
Pulmonary
hypertension;
Hypoxia;
Phosphodiesterase  5
cases, thus  adjunctive  therapies  should  be  evaluated.  In  this  report,  we  present  a  patient
with OHS-associated  PH  who  was  successfully  treated  by  tadalaﬁl  in  conjunction  with  weight
reduction  and  bi-level  positive  airway  pressure  therapy.
© 2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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ase report
 76-year-old  female  was  admitted  to  our  hospital  due
o  daytime  consciousness  disturbance  and  edema  in  lower
xtremities.  She  had  an  18-year  history  of  obesity  hypoven-
ilation  syndrome  (OHS)  without  treatment.  Her  height  was
51  cm  and  weight  was  88  kg  (BMI  38.6  kg/m2) on  admission.
er  arterial  blood  gas  analysis  revealed  signiﬁcant  hyper-
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oi:10.1016/j.jccase.2011.06.004apnia  and  resulting  respiratory  acidosis  (Table  1).  She  was
gain  given  the  diagnosis  of  OHS,  and  treated  with  commer-
ially  available  noninvasive  bi-level  positive  airway  pressure
herapy  (Autoset  CS,  TEIJIN,  Tokyo,  Japan)  with  2  L  of  sup-
lemental  oxygen.  Since  pulmonary  hypertension  (PH)  and
ight  heart  failure  were  suspected  by  echocardiography,  con-
entional  treatment  for  PH  was  started  with  40  mg/day  of
urosemide  and  3  mg/day  of  warfarin,  together  with  base-
ine  medical  treatment  of  5  mg/day  of  amlodipine,  8  mg/day
f  benidipine,  12  mg/day  of  candesartan,  and  5  mg/day
f  atorvastatin  after  her  admission.  Weight-reducing  diet
1000  kcal/day)  and  exercise  therapies  were  also  started.
fter  a  month  of  day-long  bi-level  positive  airway  pressure
herapy,  we  performed  right  heart  catheterization  (RHC)
 Published by Elsevier Ltd. All rights reserved.
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Table  1  Clinical  course  presenting  effectiveness  of  bi-level  positive  airway  pressure  and  tadalaﬁl  therapy.
On  admission  1  month  after  admission  3  months  after  admission
Clinical  settings  Oxygen  mask
(7 L  O2)
Bi-level  positive  airway
pressure  (2  L  O2)
Oxygen
loading
Bi-level  positive  airway
pressure  (2  L  O2)
+  tadalaﬁl  40  mg/day
ABG analysis
pH  7.194  7.410  NA  7.427
PO2,  mmHg  104.0  59.3  NA  83.9
PCO2,  mmHg  86.5 45.2  NA  39.4
HCO3−,  mEq/L 32.0 28.1 NA  25.5
Pulmonary  function  test
FEV1.0,  %  NA 69.7 — 73.0
%VC,  %  NA  83.7  —  83.3
Body weight,  kg  88.0  73.6  —  68.5
Body mass  index,  kg/m2 38.6  32.3  —  30.0
Systemic BP  (s/d),  mmHg  150/105  135/75  —  112/54
RHC ﬁndings
PAP  (s/d/m),  mmHg  NA  46/20/30  38/16/25  31/14/21
PCWP, mmHg  NA  10  7  7
RAP, mmHg  NA  5  5  5
Heart rate,  beats/min  NA  82  76  84
Cardiac output,  L/min  NA  9.55  8.55  9.84
Cardiac index,  L/min/m2 NA  5.50  4.92  5.82
PVR, dynes  s  cm−5 NA  168  168  114
SvO2,  %  NA  55.8  82.4  78.4
Data for oxygen loading test were acquired after 10 minutes supplementation of 10 L of oxygen with face mask. ABG, arterial blood
gas; BP, blood pressure; FEV1.0, forced expiratory volume in one second; NA, not available; PAP, pulmonary arterial pressure; PCWP,
sistan
ity.
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epulmonary capillary wedge pressure; PVR, pulmonary vascular re
SvO2, mixed venous oxyhemoglobin saturation; %VC, % vital capac
which  conﬁrmed  that  PH  existed  (Table  1).  Oxygen  load-
ing  test  reduced  pulmonary  arterial  pressure  by  decreasing
cardiac  output.  However,  hypoxia-induced  vasoconstriction
was  excluded  because  pulmonary  vascular  resistance  did
not  change  by  oxygen  loading  (Table  1).  She  had  no  history
of  smoking,  cocaine,  or  appetite  suppressant  drug  abuse.
Comprehensive  interpretation  of  diagnostic  test  ﬁndings
including  chest  radiograph,  electro-,  and  echocardiogra-
phy,  laboratory  data,  pulmonary  function  test,  enhanced
computed  tomography,  lung  perfusion  scintigraphy,  and
right  heart  catheterization  reached  the  diagnosis  of  OHS-
associated  PH  (Table  1  and  Fig.  1).  Any  other  possible
causes  of  hypoventilation  or  PH  were  excluded  with  the
tests.  Evaluation  of  concomitant  obstructive  sleep  apnea
syndrome  with  polysomnography  was  not  performed  in  this
patient  following  pulmonologist’s  advice  to  avoid  critical
risks  of  respiratory  failure  associated  with  the  examina-
tion.  She  was  then  treated  with  40  mg/day  of  tadalaﬁl
against  remaining  PH.  Finally,  RHC  demonstrated  signiﬁ-
cant  improvements  in  PH  at  3  months  after  the  admission
(Table  1).
Discussion
OHS  is  deﬁned  as  obesity  (BMI  >  30  kg/m2)  associated
with  a  daytime  hypercapnia  (arterial  carbon  dioxide  ten-
sion  >  45  mmHg)  in  the  absence  of  any  other  causes  of
hypoventilation  [1].  It  is  often  associated  with  PH  and  one
effective  choice  of  treatment  for  OHS-associated  PH  is  bi-
r
i
a
ice; RAP, right atrial pressure; RHC, right heart catheterization;
evel  positive  airway  pressure  therapy  [1,2]. However,  since
H  is  associated  with  poor  prognosis  and  bi-level  positive
irway  pressure  therapy  alone  cannot  normalize  pulmonary
rterial  pressure  in  many  cases,  adjunctive  therapy  should
e  evaluated  [2].
Tadalaﬁl  is  a phosphodiesterase  5  (PDE5)  inhibitor  that
otentiates  a  vasodilatory  effect  of  nitric  oxide,  and  is
ommonly  used  for  the  treatment  of  pulmonary  arterial
ypertension  [3].  Tadalaﬁl  may  also  have  impact  on  systemic
rteries,  as  23  mmHg  reduction  of  systolic  blood  pressure
as  seen  in  this  case  after  the  administration  of  tadalaﬁl.
t  is  reported  that  patients  with  obstructive  sleep  apnea
yndrome  present  lower  vascular  nitric  oxide  concentration
han  healthy  subjects  due  to  hypoxia-induced  endothelial
isruption  [4].  This  decrease  of  nitric  oxide  may  lead  to
ulmonary  vasoconstriction  and  resulted  in  PH  [3,4]. Thus,
e  hypothesized  that  tadalaﬁl  may  be  effective  in  treating
HS-associated  PH  by  augmenting  the  effect  of  nitric  oxide
nd  preventing  vasoconstriction.  A  marked  improvement  in
H  with  tadalaﬁl  in  this  patient  supports  our  speculation
Table  1).
There  are  several  mechanisms  that  lead  to  hypoventila-
ion  and  resultant  PH  in  obese  individuals,  such  as  increased
pper-airway  resistance  and  excessive  mechanical  load  by
xcess  weight  around  these  systems  [1].  Thus,  5.1  kg  weight
eduction  after  tadalaﬁl  therapy  may  have  a  beneﬁcial
mpact  on  PH  in  this  patient.  However,  since  bi-level  positive
irway  pressure  therapy  might  get  rid  of  these  problems  of
ncreased  upper-airway  resistance  and  excessive  mechanical
e128  S.  Katsuragi  et  al.
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[igure  1  Enhanced  chest  computed  tomography  (A)  and  (B)  
r pulmonary  embolism.
oad  in  advance,  we  speculate  that  the  dramatic  improve-
ent  of  PH  in  this  patient  was  signiﬁcantly  attributed  to
adalaﬁl.
In  conclusion,  we  present  a  case  of  OHS-associated  PH
ho  was  successfully  treated  by  tadalaﬁl  in  conjunction
ith  weight  reduction  and  bi-level  positive  airway  pres-
ure  therapy.  The  efﬁcacy  of  this  therapy  was  conﬁrmed
y  consecutive  RHC.  To  the  best  of  our  knowledge,  this  is
he  ﬁrst  report  to  show  the  effectiveness  of  tadalaﬁl  in
 patient  with  OHS-associated  PH.  We  propose  that  PDE5
nhibitors  should  be  considered  as  an  adjunctive  treatment
or  OHS-associated  PH.  Further  prospective  assessment  of
his  therapy  is  necessary  to  verify  our  conclusion.eferences
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